Welcome to our dedicated page for Marimed SEC filings (Ticker: MRMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MariMed Inc. (MRMD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly updates, and annual reports filed with the U.S. Securities and Exchange Commission. As a multi-state cannabis operator and cannabis consumer packaged goods company, MariMed uses these filings to report on its financial condition, operating performance, and material events.
Investors can review documents such as Form 8-K current reports, where MariMed furnishes press releases announcing quarterly results and other significant developments. These filings typically reference revenue, gross margin, net income or loss, and non-GAAP measures like Adjusted EBITDA and non-GAAP gross margin, along with management’s discussion of how these metrics are used to evaluate the business.
Through its periodic reports, MariMed also describes risks, uncertainties, and factors that could affect future performance, including changes in customer spending, regulatory approvals, and integration of acquired operations. Forward-looking statements in these filings are accompanied by cautionary language directing readers to additional risk discussions in the company’s reports.
On Stock Titan, each new MariMed filing is captured from the SEC’s EDGAR system and paired with AI-powered summaries that highlight key points, such as updates to financial results, explanations of non-GAAP metrics, and descriptions of material events. Users can quickly scan these summaries, then open the full filing for deeper review. This page also helps track items like insider and executive-related disclosures when they are reported on SEC forms, giving a structured view of MariMed’s regulatory reporting history.
MariMed Inc. Chief Financial Officer Mario Pinho reported routine equity award activity. On January 15, 2026, 49,995 restricted stock units converted into 49,995 shares of common stock at a price of $0 per share, increasing his directly held common stock to 294,809 shares. As part of the same vesting event, 17,324 common shares were withheld by MariMed at $0.096 per share to satisfy tax withholding obligations, leaving Pinho with 277,485 common shares held directly after the withholding.
The underlying restricted stock unit award was originally granted on July 15, 2024 and continues to vest over time, with remaining installments scheduled on July 15, 2026, January 15, 2027 and July 15, 2027. Following this transaction, Pinho directly holds 149,985 restricted stock units, each convertible into one share of common stock.
MariMed Inc.'s Chief Financial Officer reported equity compensation activity involving restricted stock units (RSUs) that vested and converted into common shares. On 12/31/2025, 53,571 RSUs were converted into the same number of shares of common stock at an effective price of $0, increasing his directly held position to 260,538 shares. On the same date, 15,724 shares were withheld and disposed of at $0.0891 per share to cover tax obligations tied to the vesting, leaving the officer with 244,814 directly owned shares afterward. The RSU grant, originally awarded on February 18, 2025, is now fully vested with no remaining unvested units.
MariMed Inc. director Eva Selhub reported an equity compensation transaction involving restricted stock units (RSUs). On December 15, 2025, 166,985 RSUs converted into the same number of shares of MariMed common stock at a stated price of $0, reflecting the non-cash nature of the award. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 under an award agreement between MariMed and Selhub. According to the filing, these RSUs were granted in lieu of cash for a portion of her fees for serving on the Board of Directors, and she beneficially owned 482,671 shares of common stock directly after the transaction.
MariMed Inc.'s Chief Financial Officer, Mario Pinho, reported equity award activity involving restricted stock units (RSUs) and common shares. On December 15, 2025, 16,075 RSUs were converted into the same number of shares of common stock at a stated price of $0, reflecting the vesting of a stock-based award.
To cover tax withholding obligations from this vesting, 4,719 shares of common stock were withheld by MariMed at a price of $0.1071 per share. After these transactions, Pinho directly owned 206,967 shares of MariMed common stock. All RSUs from the May 9, 2025 grant are now fully vested, with no unvested units remaining under that award.
MariMed Inc. President and CEO Jon R. Levine, who is also a director and 10% owner, reported insider equity activity dated 12/15/2025. On that date, 89,859 restricted stock units vested and converted one-for-one into shares of common stock at a stated price of $0, increasing his direct holdings.
To satisfy related tax withholding obligations, 26,374 shares of common stock were withheld by MariMed at $0.1071 per share. Following these entries, Levine directly holds 21,136,200 MariMed common shares and has indirect beneficial ownership of 6,684,640 shares held by the Jon Levine Family Trust for the benefit of his spouse and children, which he formally disclaims for Section 16 purposes.
MariMed Inc. director Edward Gildea reported the conversion of restricted stock units into common stock. On December 15, 2025, 247,385 restricted stock units were settled into 247,385 shares of MariMed common stock at a stated price of $0 per share under transaction code M.
After this transaction, Gildea directly owned 905,208 shares of MariMed common stock. The RSUs were originally granted on December 5, 2025 and vested in full on December 15, 2025 as payment in stock instead of cash for a portion of his fees for serving on the company’s board of directors.
MariMed Inc.'s Chief Commercial Officer Ryan Crandall reported stock-based compensation and related share movements dated December 15, 2025. He converted previously granted restricted stock units (RSUs) into 62,902 shares of common stock at a stated price of $0, and 18,462 shares were withheld to cover tax obligations, leaving him with 867,515 common shares held directly after the transactions.
On the same date, Crandall received a new grant of 1,000,000 RSUs, each convertible into one share of MariMed common stock. These RSUs were issued in lieu of a cash salary increase tied to his promotion to Chief Commercial Officer and will vest in four equal installments on June 15, 2026, December 15, 2026, June 15, 2027 and December 15, 2027.
MariMed Inc. director David R. Allen reported the conversion of restricted stock units into 176,389 shares of common stock on December 15, 2025. The transaction is shown as an acquisition at a price of $0, reflecting the settlement of equity awards rather than a cash purchase.
After this transaction, Allen directly beneficially owns 476,144 shares of MariMed common stock. The RSUs converted on a one-for-one basis, were granted on December 5, 2025, and vested in full on December 15, 2025. They were granted in lieu of cash as payment for a portion of his fees for serving on MariMed’s board of directors.
MariMed Inc.'s Chief Operating Officer Timothy Shaw reported recent stock transactions. On December 12, 2025 he purchased 45,455 shares of common stock at $0.1071 per share. On December 15, 2025, 81,772 restricted stock units vested and converted into common shares, and 24,001 shares were withheld by the company to satisfy tax withholding obligations at $0.1071 per share.
After these transactions, he directly beneficially owned 9,294,541 shares of MariMed common stock. An additional 2,000,000 shares are held indirectly through the Shaw Family Trust for the benefit of his children, for which he disclaims beneficial ownership, and no restricted stock units remain unvested under the May 23, 2025 grant.
MariMed Inc.'s Chief Commercial Officer reported routine equity compensation activity. On 12/08/2025, 54,000 restricted stock units (RSUs) converted into the same number of shares of common stock at an exercise price of $0, increasing his directly held shares to 838,925.
On the same date, 15,850 shares of common stock were withheld by MariMed at a price of $0.0824 per share to cover tax obligations related to the RSU vesting, leaving the officer with 823,075 shares held directly after these transactions. The RSUs convert to common stock on a one-for-one basis.
The filing notes that these RSUs were originally granted on June 8, 2023, and that the remaining 54,000 RSUs from this grant are scheduled to vest on June 8, 2026, under an award agreement between MariMed and the reporting officer.
FAQ
What is the current stock price of Marimed (MRMD)?
What is the market cap of Marimed (MRMD)?
